# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.
Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate o...
Needham reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.
JMP Securities analyst Jonathan Wolleben reiterates Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and maintain...